Her-2/neu and breast cancer.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Diagnostic molecular pathology (Print)

• Publication date

  2001-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00019606-200109000-00001PMID 11552716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The relationship between prognostic and predictive factors in the management of breast cancer

  2004cited by this paper
• Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?

  2004cited by this paper
• The neu-protein and breast cancer

  2004cited by this paper
• Routinely available indicators of prognosis in breast cancer

  2004cited by this paper
• c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients

  2004cited by this paper
• Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy

  2004cited by this paper
• The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer

  2004cited by this paper
• Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

  2001cited by this paper
• Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.

  2001cited by this paper
• Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

  2001cited by this paper
• Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.

  2001cited by this paper
• Cancer statistics, 2000

  2000cited by this paper
• HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With Survival

  2000cited by this paper
• HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement.

  2000cited by this paper
• Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study.

  2000cited by this paper
• Testing for erbB-2 by immunohistochemistry in breast cancer.

  2000cited by this paper
• Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

  2000cited by this paper
• Automation of Fluorescence In Situ Hybridization Pretreatment: A Comparative Study of Different Sample Types

  2000cited by this paper
• Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization

  2000cited by this paper
• HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach

  2000cited by this paper
• Experts debate value of HER2 testing methods.

  2000cited by this paper
• Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.

  2000cited by this paper
• Differences in breast cancer prognosis among African‐American and Caucasian women

  2000cited by this paper
• Resistance to taxanes is induced by c‐erbB‐2 overexpression in human MCF‐10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A

  2000cited by this paper
• Global breast cancer mortality statistics

  1999cited by this paper
• The HercepTest assay: another perspective.

  1999cited by this paper
• Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.

  1999cited by this paper
• Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.

  1999cited by this paper
• Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

  1999cited by this paper
• The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.

  1999cited by this paper
• Basic science of HER-2/neu: a review.

  1999cited by this paper
• Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.

  1999cited by this paper
• Immunohistochemical assays for HER2 overexpression.

  1999cited by this paper
• Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.

  1999cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• Clinical highlights from the National Cancer Data Base, 1999

  1999cited by this paper
• Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.

  1999cited by this paper
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

  1999cited by this paper
• HER-2/neu (c-erb-B2) gene and protein in breast cancer.

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Increased HER2 with U.S. Food and Drug Administration-approved antibody.

  1999cited by this paper
• neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.

  1998cited by this paper
• Reproducibility of LSI HER-2/neu SpectrumOrange and CEP 17 SpectrumGreen Dual Color deoxyribonucleic acid probe kit. For enumeration of gene amplification in paraffin-embedded specimens: a multicenter clinical validation study.

  1998cited by this paper
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  1998cited by this paper
• Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

  1998cited by this paper
• Cytoplasmic staining of c‐erbB‐2 is not associated with the presence of detectable c‐erbB‐2 mRNA in breast cancer specimens

  1998cited by this paper
• Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

  1998cited by this paper
• erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

  1998cited by this paper
• Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.

  1998cited by this paper
• The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

  1998cited by this paper
• erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

  1998cited by this paper
• Variability of immunohistochemical reactivity on stored paraffin slides.

  1998cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.

  1998cited by this paper
• HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

  1998cited by this paper
• Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization

  1997cited by this paper
• erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody.

  1997cited by this paper
• A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

  1997cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.

  1997cited by this paper
• Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.

  1997cited by this paper
• Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

  1996cited by this paper
• c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

  1996cited by this paper
• Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.

  1996cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer.

  1996cited by this paper
• The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.

  1995cited by this paper
• HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

  1995cited by this paper
• Gene diagnostics provide new insights into breast cancer prognosis and therapy.

  1995cited by this paper
• Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis

  1995cited by this paper
• The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases

  1995cited by this paper
• Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research

  1995cited by this paper
• Drug therapy : paclitaxel (Taxol)

  1995cited by this paper
• MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo

  1995cited by this paper
• Paclitaxel (taxol)

  1995cited by this paper
• Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

  1994cited by this paper
• Prognostic significance of HER‐2/neu oncoprotein expression in node‐positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

  1994cited by this paper
• Prognostic value of c‐erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol

  1994cited by this paper
• Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation

  1994cited by this paper
• C-erbB-2 immunostaining: problems with interpretation.

  1994cited by this paper
• Overview of the biologic markers of breast cancer.

  1994cited by this paper
• c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

  1994cited by this paper
• The biology of erbB-2/neu/HER-2 and its role in cancer.

  1994cited by this paper
• ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.

  1994cited by this paper
• Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior.

  1994cited by this paper
• Analysis Of Cerbb2 Expression Using A Panel Of 6 Commercially Available Antibodies

  1994cited by this paper
• Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

  1994cited by this paper
• Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.

  1993cited by this paper
• Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

  1993cited by this paper
• Prognostic significance of c-erbB-2 expression in node negative breast cancer.

  1993cited by this paper
• neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer.

  1993cited by this paper
• Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth.

  1993cited by this paper
• Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

  1993cited by this paper
• Cell biological factors associated with the response of breast cancer to systemic treatment.

  1993cited by this paper
• Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

  1992cited by this paper
• Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor.

  1992cited by this paper
• HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.

  1992cited by this paper
• C‐erbb‐2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node‐positive breast cancer

  1992cited by this paper
• Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.

  1992cited by this paper
• Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.

  1992cited by this paper

• Clinicopathological Features of HER2 Expressing Lobular Carcinoma of Breast

  2025cites this paper
• Breast Cancer and Meningioma Risk: A Mendelian Randomization Study

  2025cites this paper
• Expression of Her-2 and Ki-67 in Gastric Cancer Formalin Fixed Paraffin Embedded Tissue Blocks and Their Correlation with Histological Grades at the Uganda Cancer Institute Pathology Laboratory

  2024cites this paper
• A review of cutaneous apocrine carcinoma: epidemiology, diagnosis, prognosis, and treatment options.

  2024cites this paper
• Evaluation of HER2/Neu Receptors and Its Comparison with Pathologic Parameters in Rural Breast Cancer Patients in Eastern India

  2024cites this paper
• Tissue Biomarkers in Gastric Cancer Treatment: Present and Future

  2024cites this paper
• Clinical significance of Talin-1 and HER-2 status in different types of gastric carcinoma

  2024cites this paper
• Targeting STAT3 signaling pathway by curcumin and its analogues for breast cancer: A narrative review

  2024cites this paper
• Exploring the Frontier of Biopolymer-Assisted Drug Delivery: Advancements, Clinical Applications, and Future Perspectives in Cancer Nanomedicine

  2024cites this paper
• Advancement in Biopolymer Assisted Cancer Theranostics

  2023cites this paper
• Detection of ERBB2 and CEN17 signals in fluorescent in situ hybridization and dual in situ hybridization for guiding breast cancer HER2 target therapy

  2023cites this paper
• Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer

  2022cites this paper
• Squalamine and Its Aminosterol Derivatives: Overview of Biological Effects and Mechanisms of Action of Compounds with Multiple Therapeutic Applications

  2022cites this paper
• Prognostic significance of preoperative computed hematological inflammatory parameters in patients with breast cancer

  2022cites this paper
• A Systematic Review of Biosynthesized Metallic Nanoparticles as a Promising Anti-Cancer-Strategy

  2021cites this paper
• Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models

  2021cites this paper
• Risk factors at five-year survival in grade 3 breast cancer: a retrospective observational study of the New Zealand population

  2021cites this paper
• Defining Breast Cancer

  2021cites this paper
• Osteopontin and breast cancer metastasis: possible role of genistein on the regulation of osteopontin

  2021cites this paper
• HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features

  2021cites this paper
• Single-Institute Review of HER-2/Neu-Positive Invasive Lobular Breast Carcinoma in an Arab Population

  2021cites this paper
• Biobanks in oncology: global experience and Russian reality

  2020cites this paper
• Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam

  2020cites this paper
• Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells

  2020cites this paper
• Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam.

  2020cites this paper
• Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results

  2019cites this paper
• Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer

  2019cites this paper
• Differential expression of HER2 and downstream proteins in prediction of advanced tumor phenotypes and overall survival of patients with Epstein-Barr virus-positive vs. negative gastric cancers.

  2019cites this paper
• CEG_A_212895 287..294

  2019cites this paper
• HER-2/Neu and Hormone Receptor Analysis in Breast Carcinomas and Their Association with Clinicopathologic Parameters.

  2019cites this paper
• Audit of Grade 3 Breast Cancer in New Zealand Women

  2019cites this paper
• HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran

  2018influential citation
• The Differences of Age, Tumor Grade, and Her2 Amplification in Estrogen and Progesterone Receptor Status in Patients with Breast Cancer

  2018cites this paper
• Association of Her-2 Expression and Clinicopathological Parameters in Colorectal Carcinoma in Indian Population

  2018cites this paper
• VDR independent induction of acid-sphingomyelinase by 1,23(OH)2 D3 in gastric cancer cells: Impact on apoptosis and cell morphology.

  2018cites this paper
• Prognostic Significance of Vascular Endothelial Growth Factor (VEGF) and Her-2 Protein in the Genesis of Cervical Carcinoma

  2018cites this paper
• Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in Urothelial Carcinomas

  2017cites this paper
• Immunohistochemical Study of HER2/neu Expression in Colorectal Cancer and its Relation to other Clinicopathological Criteria and Prognostic Factors

  2017cites this paper
• Correlation of Hormone Receptor and Human Epidermal Growth Factor Receptor-2/neu Expression in Breast Cancer with Various Clinicopathologic Factors

  2017cites this paper
• Down-regulation of hK7 in the sera of breast cancer and benign breast disease patients

  2017cites this paper
• Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice.

  2017cites this paper
• Gene copy number variation and protein overexpression of EGFR and HER2 in distal extrahepatic cholangiocarcinoma.

  2017cites this paper
• Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer

  2017cites this paper
• A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry

  2017cites this paper
• A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry.

  2017cites this paper
• Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.

  2016cites this paper
• Correlation of Her-2/neu Status With Estrogen, Progesterone Receptors and Histologic Features in Breast Carcinoma

  2016cites this paper
• Triple Negative Breast Cancer in a Private Immunohistochemistry Laboratory in Abuja Nigeria

  2016cites this paper
• Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition

  2016cites this paper
• Does single receptor positive breast carcinoma differ with regard to age, tumor grade, and HER2 amplification status?

  2016cites this paper
• How to Build Up Adequate Prognostic Markers in the Molecular Biology Context of Breast Cancer

  2016cites this paper
• Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model.

  2016cites this paper
• MicroRNAs: mediators of EGFR targeted therapy resistance in renal cell carcinoma

  2016cites this paper
• Introduction Does single receptor positive breast carcinoma differ with regard to age , tumor grade , and HER 2 amplification status ?

  2016cites this paper
• Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab

  2016cites this paper
• The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis

  2016cites this paper
• miRNAs: mediators of ErbB family targeted therapy resistance.

  2016cites this paper
• HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India

  2015cites this paper
• Evaluation of Expression of Her2/neu in Gastric Cancer and Its Significance as a Prognostic Factor in Gastric Adenocarcinoma

  2015cites this paper
• High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients.

  2015cites this paper
• The clinical significance of HER2 protein amplification/expression in urinary bladder lesion

  2015cites this paper
• Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer

  2015cites this paper
• Impact of age, tumor size, lymph node metastasis, stage, receptor status and menopausal status on overall survival of breast cancer patients in Pakistan.

  2015cites this paper
• Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization

  2015cites this paper
• HER2 Testing in Gastric and Gastroesophageal Adenocarcinomas

  2015cites this paper
• HER2 expression variability between primary gastric cancers and corresponding lymph node metastases.

  2015cites this paper
• Association between GSTP1 genotypes and hormone receptor phenotype in invasive ductal carcinomas of breast.

  2015cites this paper
• Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

  2015cites this paper
• The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies

  2014cites this paper
• HORMONE RECEPTOR STATUS AND HER-2/NEU EXPRESSION IN BREAST CARCINOMA AND ITS CORRELATION WITH CLINICO-PATHOLOGICAL FEATURES: A STUDY AT MEDICAL COLLEGE HOSPITAL

  2014cites this paper
• Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?

  2014cites this paper
• Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy

  2014cites this paper
• Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis

  2014cites this paper
• Overexpression of Her-2 upregulates FoxM1 in gastric cancer.

  2014cites this paper
• HER-2 overexpression and survival in colorectal cancer: a meta-analysis

  2014cites this paper
• Breast carcinoma, Hormone receptors, Her-2/neu expression and tumor grading.

  2014cites this paper
• Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients

  2014cites this paper
• HER2 STATUS BREAST CANCER IN A POPULATION OF WESTERN ALGERIA

  2013cites this paper
• Correlation of human epidermal growth factor receptor 2 (HER-2/neu) receptor status with hormone receptors Oestrogen Receptor, Progesterone Receptor status and other prognostic markers in breast cancer: an experience at tertiary care hospital in Karachi.

  2013cites this paper
• Indications et gestion des effets secondaires

  2013cites this paper
• Comparison of Oestrogen Receptor, Progesterone Receptor, and Human Epiderman Growth Factor Receptor-2 Expression in Primary Breast Cancer and Lymph Node Metastasis at the Korle-Bu Teaching Hospital, Accra, Ghana

  2013cites this paper
• Clinical role of HER-2/neu expression in colorectal cancer.

  2013cites this paper
• HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma

  2013cites this paper
• Bioengineering strategies for designing targeted cancer therapies.

  2013cites this paper
• Are Biopsy Specimens Predictive of HER2 Status in Gastric Cancer Patients?

  2012cites this paper
• Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan

  2012cites this paper
• Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial

  2012cites this paper
• Evaluation of CA 15-3, Her-2/neu and estrogen/progesterone status in breast cancer patients treated by surgical removal and chemotherapy

  2012cites this paper
• Association between Overexpression of Her-2 and Other Clinicopathologic Prognostic Factors in Breast Cancer in Morocco

  2012cites this paper
• HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients

  2012cites this paper
• Expression and association of HER2 with prognosis in early-stage (T1–T2N0M0) non-small cell lung cancer

  2012cites this paper
• möglicher neuer Angriffspunkt in der targeted therapy des Mammakarzinoms

  2012cites this paper
• Circulating levels of HER-2/neu oncoprotein in breast cancer

  2012cites this paper
• MALDI imaging mass spectrometry in clinical proteomics research of gastric cancer tissues

  2012cites this paper
• Clinical Significance of HER2/neu Overexpression in Advanced Gastric Cancer

  2012cites this paper
• ROLE OF RECEPTORS IN BREAST CANCER

  2012cites this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.

  2012cites this paper
• Integration of DNA Copy Number Alterations and Transcriptional Expression Analysis in Human Gastric Cancer

  2012cites this paper
• Neue diagnostische Marker bei Mammakarzinompatientinnen

  2011influential citation
• CARCINOMA BREAST-HISTOPATHOLOGICAL AND HORMONE RECEPTORS CORRELATION

  2011cites this paper